Management of Heart Failure with Reduced Ejection Fraction in Patients with COPD

Introduction to Guideline-Directed Medical Therapy

The American College of Cardiology recommends initiation of quadruple guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), which provides a 73% mortality reduction over 2 years, in patients with COPD 1
The European Society of Cardiology suggests that the presence of COPD should not prevent aggressive HF treatment, and GDMT should be initiated simultaneously with COPD management 1

Assess for fluid overload by examining for peripheral edema, elevated jugular venous pressure, rapid weight gain (>2 kg in 3 days), and pulmonary congestion, as recommended by the European Journal of Heart Failure 2, 1
If fluid overload is present, initiate loop diuretics immediately for rapid symptom relief before starting or alongside GDMT, according to Praxis Medical Insights 1
Monitor daily weights with patient education on self-monitoring and flexible diuretic adjustment, as suggested by the European Journal of Heart Failure 2

Initiate all four medication classes simultaneously for most rapid mortality benefit and symptom relief, as recommended by Praxis Medical Insights 1
Start sacubitril/valsartan as first-line therapy, which provides ≥20% mortality reduction versus 5-16% for ACE inhibitors/ARBs, according to Praxis Medical Insights 3, 4
Target dose: 97/103 mg twice daily, as suggested by Praxis Medical Insights 1
If ARNI not feasible, use ACE inhibitor (e.g., lisinopril up to 35 mg daily based on ATLAS trial showing favorable outcomes at higher doses), as recommended by Praxis Medical Insights 4

Use forced-titration approach with medication adjustments every 1-2 weeks until target doses are achieved, as recommended by Praxis Medical Insights 1, 3
Target achievement within 2 months of initiation, according to Praxis Medical Insights 1
Early follow-up within 7-14 days after each medication adjustment, as suggested by Praxis Medical Insights 1, 3

Provide comprehensive education on both conditions to improve adherence and outcomes, as recommended by the European Journal of Heart Failure 5, 2
Explain that dyspnea and anxiety will improve with medication optimization, according to Praxis Medical Insights 1
Teach daily weight monitoring and recognition of worsening symptoms (increased dyspnea, edema, rapid weight gain), as suggested by the European Journal of Heart Failure 2

Implement standardized multidisciplinary team management from primary to tertiary care levels, as recommended by the European Journal of Heart Failure 5, 2
Involve cardiologists, primary care physicians, nurses, pharmacists in coordinated care, according to the European Journal of Heart Failure 2
Ensure seamless transition of care and regular communication between providers, as suggested by the European Journal of Heart Failure 5

Prescribe supervised exercise training program once stable, as recommended by the European Journal of Heart Failure 2
Physical conditioning improves exercise tolerance, quality of life, and reduces HF hospitalization rates, according to the European Journal of Heart Failure 2

Structured monitoring protocol, as recommended by Praxis Medical Insights 1, 3
Week 1-2: Initial follow-up after GDMT initiation, according to the European Journal of Heart Failure 5
Every 1-2 weeks: Uptitration visits until target doses achieved, as suggested by Praxis Medical Insights 3

Never discontinue GDMT even if ejection fraction improves—discontinuation leads to clinical deterioration, as recommended by Praxis Medical Insights 1, 3
Continue all HFrEF medications indefinitely regardless of EF improvement, according to Praxis Medical Insights 3
Avoid excessive diuresis before starting ACE inhibitors/ARNI, as this can cause hypotension and renal dysfunction, as suggested by Praxis Medical Insights 1

Consider cardiac resynchronization therapy (CRT) if QRS duration is prolonged (>130-150 ms) despite optimal medical therapy, as recommended by Praxis Medical Insights 3
Manage comorbidities aggressively: hypertension, diabetes, obesity, atrial fibrillation, coronary artery disease, chronic kidney disease, according to Praxis Medical Insights 4
Provide psychosocial support to patient and family/caregivers given high symptom burden and mortality risk, as suggested by the European Journal of Heart Failure 2
Ensure medication affordability: Advocate for full reimbursement to relieve financial burden and enable GDMT implementation, according to the European Journal of Heart Failure 5